NEOPLASMA

Scope & Guideline

Pioneering Insights in Neoplastic Diseases

Introduction

Welcome to the NEOPLASMA information hub, where our guidelines provide a wealth of knowledge about the journal’s focus and academic contributions. This page includes an extensive look at the aims and scope of NEOPLASMA, highlighting trending and emerging areas of study. We also examine declining topics to offer insight into academic interest shifts. Our curated list of highly cited topics and recent publications is part of our effort to guide scholars, using these guidelines to stay ahead in their research endeavors.
LanguageEnglish
ISSN0028-2685
PublisherAEPRESS SRO
Support Open AccessNo
CountrySlovakia
TypeJournal
Convergefrom 1957 to 2024
AbbreviationNEOPLASMA / Neoplasma
Frequency6 issues/year
Time To First Decision-
Time To Acceptance-
Acceptance Rate-
Home Page-
AddressBAJZOVA 7, BRATISLAVA 821 08, SLOVAKIA

Aims and Scopes

NEOPLASMA is a peer-reviewed journal that focuses on various aspects of cancer research, including molecular mechanisms, clinical studies, and innovative therapeutic strategies. The journal aims to provide a platform for researchers to share their findings and insights on the complexities of cancer biology and treatment.
  1. Molecular Mechanisms of Cancer:
    Research focusing on the underlying biological processes and molecular pathways that contribute to cancer development and progression, including studies on gene expressions, signaling pathways, and cellular interactions.
  2. Therapeutic Strategies and Clinical Trials:
    Papers that explore novel treatments, drug combinations, and clinical trial results aimed at improving patient outcomes in various cancer types.
  3. Cancer Biomarkers and Diagnostics:
    Studies aimed at identifying and validating biomarkers for cancer diagnosis, prognosis, and treatment response, facilitating personalized medicine approaches.
  4. Tumor Microenvironment and Metastasis:
    Research that investigates the interactions between tumor cells and their microenvironment, including the role of stromal cells, immune responses, and metastatic behavior.
  5. Preclinical and Translational Research:
    Emphasis on the development of innovative models and methodologies to study cancer, including in vitro and in vivo studies that bridge laboratory findings to clinical applications.
In recent years, NEOPLASMA has seen a notable increase in the publication of research focused on innovative and interdisciplinary approaches to cancer treatment and understanding. These emerging themes reflect the evolving landscape of cancer research.
  1. Targeted and Personalized Therapies:
    An increasing number of studies are focusing on targeted therapies, particularly those tailored to specific genetic mutations and biomarkers, indicating a shift towards precision medicine in oncology.
  2. Immunotherapy and Immune Checkpoint Inhibitors:
    Research examining the mechanisms and efficacy of immunotherapies, particularly immune checkpoint inhibitors, is on the rise as these treatments become central to cancer management.
  3. Ferroptosis and Novel Cell Death Mechanisms:
    Emerging interest in ferroptosis and other forms of regulated cell death as potential therapeutic targets reflects a deeper understanding of cancer biology and treatment resistance.
  4. MicroRNA and Long Non-Coding RNA Research:
    Studies exploring the roles of microRNAs and long non-coding RNAs in cancer progression and therapy resistance are increasingly prevalent, highlighting the importance of non-coding RNA in tumor biology.
  5. Cancer Metabolism and Metabolic Reprogramming:
    Research focusing on the metabolic adaptations of cancer cells and how these can be targeted for therapeutic benefit is gaining traction, reflecting a broader interest in cancer cell biology.

Declining or Waning

While NEOPLASMA continues to be a leading journal in cancer research, certain themes have shown a decline in publication frequency, reflecting shifts in research priorities and emerging interests in the field.
  1. Traditional Chemotherapy Studies:
    Research focused solely on traditional chemotherapy regimens is less frequent, as there is a growing emphasis on targeted therapies and immunotherapy approaches.
  2. Basic Histopathological Studies:
    Papers that primarily describe histopathological features without integrating molecular or genetic analyses are becoming less prominent, reflecting a shift towards more comprehensive approaches that combine multiple disciplines.
  3. Single-Agent Drug Studies:
    There is a noticeable decline in studies investigating the efficacy of single-agent therapies, as combination therapies and multi-modal treatment strategies are gaining more attention.
  4. Non-Clinical Research:
    Research that lacks translational relevance or direct clinical implications is decreasing, as the focus shifts towards studies that can directly inform clinical practice and patient care.

Similar Journals

MOLECULAR CANCER THERAPEUTICS

Connecting science and healing in the fight against cancer.
Publisher: AMER ASSOC CANCER RESEARCHISSN: 1535-7163Frequency: 12 issues/year

MOLECULAR CANCER THERAPEUTICS, published by the American Association for Cancer Research, is a premier journal dedicated to advancing the field of cancer research and therapy since 2001. With a notable impact factor reflecting its high-quality content, this journal stands out in the Q1 category for both Cancer Research and Oncology as of 2023. Researchers, clinicians, and students interested in innovative treatment strategies and molecular mechanisms can find valuable insights within its pages, bolstered by a rigorous peer-review process and a global perspective on cancer therapeutic developments. Although the journal operates under a subscription model, it provides comprehensive access to cutting-edge studies and reviews that drive forward the understanding of cancer biology and treatment modalities. The journal's impressive Scopus rankings further validate its influence within both oncology and the broader cancer research community, making it an indispensable resource for anyone committed to combating cancer through science.

CANCER LETTERS

Elevating the discourse in cancer science.
Publisher: ELSEVIER IRELAND LTDISSN: 0304-3835Frequency: 28 issues/year

Cancer Letters, a leading journal published by Elsevier Ireland Ltd, is dedicated to advancing the field of oncology and cancer research. With a rich history that spans from 1975 to 2024, this esteemed journal has established itself as a vital resource within the scientific community, holding a prestigious Q1 status in both Cancer Research and Oncology categories as of 2023. With an impressive ranking of #26/404 in Medicine _ Oncology and #19/230 in Biochemistry, Genetics and Molecular Biology _ Cancer Research, Cancer Letters sits in the top percentiles of its field, reflecting its high impact and relevance. Although it does not currently offer open access, the journal remains committed to disseminating paramount research findings, innovative methodologies, and critical reviews that inform and enhance ongoing studies in cancer therapeutics and patient care. Researchers, professionals, and students alike will find invaluable insights into the latest developments and discoveries in cancer research through the pages of Cancer Letters.

Annual Review of Cancer Biology

Elevating Understanding in Cancer Research
Publisher: ANNUAL REVIEWSISSN: 2472-3428Frequency: 1 issue/year

Annual Review of Cancer Biology is a pivotal journal published by Annual Reviews, specializing in the rapidly evolving field of cancer research. With an impact factor positioned in the distinguished Q1 quartile of Cancer Research, Cell Biology, and Oncology categories, this journal ensures that it showcases the highest quality of scholarly contributions. Indexed in Scopus, it ranks among the top in its fields, reflecting its strong influence and relevance, with remarkable percentiles indicating its esteemed position within the research community. Although not an open-access journal, it provides a comprehensive platform for advancing the frontiers of cancer biology through rigorously curated reviews, highlighting key developments, breakthroughs, and future directions that inform both academia and clinical applications. As a valuable resource for researchers, professionals, and students, the Annual Review of Cancer Biology serves as an essential guide for understanding and addressing the complexities of cancer biology today.

Blood Cancer Discovery

Transforming Research into Life-Saving Solutions
Publisher: AMER ASSOC CANCER RESEARCHISSN: 2643-3230Frequency: 6 issues/year

Blood Cancer Discovery is a premier academic journal published by the American Association for Cancer Research, dedicated to advancing the understanding of hematologic malignancies through cutting-edge research in the fields of oncology, biochemistry, and molecular biology. With an impressive impact factor and recognition as a Q1 journal across multiple disciplines, including cancer research and hematology, Blood Cancer Discovery serves as an essential platform for scholars and practitioners alike, facilitating impactful discourse and dissemination of pioneering findings. This open-access journal, established within the vibrant academic landscape of the United States, aims to bridge gaps in research and foster collaborations to ultimately enhance patient outcomes. Its Scopus rankings demonstrate its vital role in the critical advancement of cancer research and therapeutic development. By inviting contributions from a diverse range of disciplines, Blood Cancer Discovery is poised to drive innovation and inspire future advancements in understanding blood cancers.

JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH

Empowering the global fight against cancer with open access.
Publisher: BMCISSN: Frequency: 1 issue/year

The JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH, published by BMC, is a leading open-access journal dedicated to advancing the field of cancer research and oncology. Since its inception in 1982, this esteemed journal has fostered innovation and collaboration in the scientific community, as evidenced by its outstanding impact factor and position in the Q1 quartile for both Cancer Research and Oncology categories in 2023. With a proud commitment to disseminating high-quality research, the journal operates under an open-access model, ensuring that findings are readily accessible to researchers, healthcare professionals, and students worldwide. The journal has established a distinguished reputation, ranking 23rd out of 404 in Medicine oncology and 16th out of 230 in Biochemistry, Genetics, and Molecular Biology (cancer research), showcasing its importance and influence in guiding the future of cancer treatment and research. With the aim of bridging experimental and clinical research, this journal invites submissions that push the boundaries of our understanding of cancer biology and therapy.

Molecular & Cellular Oncology

Connecting researchers to the forefront of oncology.
Publisher: TAYLOR & FRANCIS INCISSN: Frequency: 6 issues/year

Molecular & Cellular Oncology, published by Taylor & Francis Inc, is a vital academic journal dedicated to the exploration of cancer biology through the lens of molecular and cellular mechanisms. Since its inception in 2014, the journal has played a crucial role in disseminating innovative research findings that address the fundamental aspects of cancer research and molecular medicine. With its current ranking in Scopus placing it in the Q3 quartile for both Cancer Research and Molecular Medicine, the journal provides a platform for groundbreaking studies that push the boundaries of our understanding of oncogenesis and therapeutic interventions. Although the journal operates under a subscription model, its dedication to high-quality peer-reviewed research makes it an essential resource for researchers, professionals, and students aiming to contribute to or stay updated in the rapidly evolving field of oncology. As we approach the culmination of its converged years in 2024, Molecular & Cellular Oncology aims to continue fostering collaborations and insights that advance cancer research on a global scale.

Cancer Cell International

Empowering Discovery in Oncology
Publisher: BMCISSN: Frequency: 1 issue/year

Cancer Cell International, published by BMC, is a transformative open-access journal established in 2001, dedicated to advancing the field of oncology and cancer research. With its ISSN number not specified and an E-ISSN of 1475-2867, the journal proudly operates from the United Kingdom, located at CAMPUS, 4 Crinan St, London N1 9XW, England. Renowned for its rigorous peer-review process, Cancer Cell International has made significant strides, securing a Q2 ranking in Cancer Research and Q1 rankings in both Genetics and Oncology as of 2023. It ranks impressively in Scopus, featuring in the top quintile of Genetics (#37/347) and Oncology (#52/404), indicating its importance within the scientific community. The journal's broad scope caters to a diverse array of topics within cancer biology, making it an invaluable resource for researchers, professionals, and students seeking to stay at the forefront of cancer science. With a commitment to disseminating high-quality research, Cancer Cell International invites scholars to explore innovative findings and contribute to the collective effort of combating cancer.

Molecular and Clinical Oncology

Transforming insights into impactful oncology practices.
Publisher: SPANDIDOS PUBL LTDISSN: 2049-9450Frequency: 12 issues/year

Molecular and Clinical Oncology is a dynamic journal published by SPANDIDOS PUBL LTD, aimed at advancing the understanding of cancer biology and treatment modalities. With an ISSN of 2049-9450 and an E-ISSN of 2049-9469, the journal serves as a critical platform for researchers and clinicians dedicated to uncovering novel insights in molecular oncology and enhancing clinical practices. As a testament to its growing influence, the journal has achieved a Q3 ranking in Oncology and a Q4 ranking in Cancer Research for the year 2023, reflecting its commitment to publishing high-quality research. Although currently not an Open Access publication, the journal offers crucial subscription options, ensuring comprehensive access to groundbreaking studies and innovations in the field. With converged years spanning 2018 to 2024, the journal is set to continue enriching the academic community with its valuable contributions, ultimately empowering researchers, professionals, and students engaged in the fight against cancer.

BIOCHIMICA ET BIOPHYSICA ACTA-REVIEWS ON CANCER

Synthesis of Cutting-Edge Cancer Discoveries
Publisher: ELSEVIERISSN: 0304-419XFrequency: 4 issues/year

BIOCHIMICA ET BIOPHYSICA ACTA-REVIEWS ON CANCER, published by Elsevier, has established itself as a leading journal in the domains of cancer research, genetics, and oncology, holding a prestigious position in the Q1 quartile rankings in these fields as of 2023. With an ISSN of 0304-419X and an E-ISSN of 1879-2561, this journal aims to disseminate high-quality, impactful reviews that synthesize the latest advancements and findings in cancer biology, treatment modalities, and genomic studies. Its robust indexing and remarkable Scopus rankings—placing it in the 95th to 91st percentiles across various categories—underline its significance for researchers, clinicians, and students passionate about oncology. Operating from its Netherlands headquarters, BIOCHIMICA ET BIOPHYSICA ACTA-REVIEWS ON CANCER is dedicated to fostering a comprehensive understanding of the complex biological mechanisms underlying cancer, promoting innovative therapeutic strategies, and guiding future research directions.

BRITISH JOURNAL OF CANCER

Transforming Cancer Care with Cutting-Edge Discoveries.
Publisher: SPRINGERNATUREISSN: 0007-0920Frequency: 24 issues/year

The British Journal of Cancer, published by SpringerNature, stands as a preeminent resource in the fields of Cancer Research and Oncology, with a distinguished history of publication dating back to 1947. With its Q1 rank in both categories for 2023, this journal is among the top-tier publications, offering cutting-edge research and insights into the biology, etiology, and treatment of cancer. The journal’s rigorous peer-review process ensures that readers are presented with high-quality studies that contribute to the advancement of cancer knowledge and clinical practice. Operating from the United Kingdom, it has garnered a notable impact factor and ranks impressively within Scopus, making it an essential publication for researchers, healthcare professionals, and students who are dedicated to understanding cancer's complexities. Access to the journal's articles is available in traditional formats, providing a versatile platform for disseminating pivotal research. As we move towards a future where cancer treatment and prevention remain crucial, the British Journal of Cancer continues to play a vital role in shaping the dialogue and discoveries within the oncology community.